Transoral robotic surgery: development and challenges

Raymond K Tsang
Department of Surgery, University of Hong Kong, Hong Kong

Abstract: The da Vinci Surgical robot has been marketed since 1999; it was originally designed for aiding complex laparoscopic operations and cardiac operations. By the mid-2000s, otolaryngologists had been attempting to deploy the surgical robot for endoscopic minimally invasive operations in the upper aerodigestive tract. The development went through a mannequin model, canine model, and cadaver model and finally cumulated to human Phase I trial. The operation was dubbed transoral robotic surgery (TORS). Subsequently, multicenter trials in the United States had proved the safety and oncological efficacy of using the surgical robot for resection of early cancers in the upper aerodigestive tract. In 2009, the US Food and Drug Administration granted license for the da Vinci surgical robot to be used for resection of benign tumors and early cancers in the oropharynx, larynx, and hypopharynx. TORS has also developed for surgery in the anterior skull base and nasopharynx, as well as in setting of flaps for reconstruction in the upper aerodigestive tract. This article will review the development of TORS, the current limitations, and future developments.

Keywords: head and neck surgery, minimally invasive surgery, computer aided surgery, endoscopic surgery

Introduction
Technology has been the driving force of medical advances. The introduction of the charged coupled device that was small enough to adapt to a rigid endoscopy enabled images of the internal organs inside the abdomen viewed by a laparoscope to be displayed on a television monitor screen. This led to the development of the first laparoscopic cholecystectomy in 1998 and endoscopic surgery has become the standard of care for a variety of diseases in many subspecialties.

Telemanipulation is a technology that enabled the movement of a remote effector (robot) to copy the movement of the operator. It is the basis of robotic arms. Raymond Geortz developed the first robotic arm with master and slave configuration for handling of radioactive substance in the Argonne National Laboratory in Chicago, USA, in 1951.

The combination of the two technologies of remote visualization and telemanipulation formed the core technology of the da Vinci surgical robot. The da Vinci surgical robot was developed by Intuitive Surgical Inc. (Sunnyvale, CA, USA). The company was founded in 1995 and the first clinical application was performed in March 1997. The operation was a laparoscopic cholecystectomy. The da Vinci surgical robot was marketed in 1999 and obtained approval for clinical use in laparoscopic surgery by the Food and Drug Administration of USA (FDA) in 2000.
The da Vinci surgical robot consisted of a control console and a patient cart. The patient cart had three and later four robotic arms that control the instruments inserted into the patient, and the patient cart is placed near the patient at the side of the operating table. One arm is reserved for controlling the endoscope for visualization. The surgeon sits on the control console, which is placed at a distance from the patient but inside the operation room. The surgeon would be able to visualize the view of the endoscope on the control console and control the movements of the robotic arms.

The da Vinci surgical robot is designed to be an augmentation of conventional laparoscopic surgery. In conventional laparoscopic surgery, the distal ends of the instruments are usually not articulated. Even if they are articulated, simultaneous control of all the joints would be difficult. Therefore, in conventional laparoscopic surgery, some degree of movement will need to be sacrificed. The major advantage of the da Vinci surgical robot is the incorporation of the EndoWrist®, which allowed 7 degrees of movement and 540 degrees of arm rotation. The distal articulation of the wristed instrument has a larger range of motion than a human wrist and is miniaturized to allow placement in tight spaces.

The other advantages of the da Vinci surgical robot include three-dimensional images, motion scaling for precise movements of the instruments, tremor filtration, and lack of fatigue. Remote surgery and remote proctoring are also added advantages in certain locations in the world where expertise may not be directly accessible.

Two years after the da Vinci surgical robot had been marketed, substantial experience was gained in abdominal surgery. After a decade of development, the use of the da Vinci surgical robot in minimally invasive surgery has shown advantages in the field of urology, gynecology, and colorectal surgery. The da Vinci surgical robot is not designed primarily for head and neck surgery, but head and neck surgeons have shown interest in adapting the da Vinci surgical robot to perform minimally invasive surgery or remote-access surgery. The use of the da Vinci surgical robot in the head and neck area can be divided into: 1) minimally invasive surgery where the surgical robot is used to perform surgical operations inside the upper aerodigestive tract without transgressing the normal tissue of the head and neck region; and 2) remote access surgery to perform surgery in the neck through incisions placed away from the organ in cosmetically acceptable regions of the neck.

The present article is a review of the current state of robotic surgery in the head and neck region, mainly focusing on the application of the da Vinci surgical robot. PubMed was the primary database consulted in preparing this review and all the literature reviewed was in English. The review is not conducted as an exhaustive literature search like a meta-analysis, but is intended to provide an overview of the current state of robotic surgery in the head and neck region. Table 1 lists the robotic procedures mentioned in the review.

### Application of the da Vinci surgical robot in upper aerodigestive tract

McLeod and Melder performed the first application of the da Vinci surgical robot in endolaryngeal surgery in 2002. The robot was used to resect a vallecular cyst. The case was a proof of concept, opening up the use of the robot in the field of head and neck surgery.

Subsequently, extensive research on application of the da Vinci surgical robot in performing endoscopic surgery in the oropharynx, larynx, and hypopharynx was performed by the University of Pennsylvania group. The study started on an airway mannequin, progressing to cadaveric dissections, and later to a canine model. After the success in the preclinical phase of the study, the group embarked on Phase I clinical trials in 2006 with case series on resection of base of tongue cancers, tonsillar cancers, and supraglottic cancers. The FDA approved the use of the da Vinci surgical robot for endoscopic resection of early T-stage (T1–T2) head and neck cancers in 2009. The operation was subsequently named “transoral robotic surgery” (TORS). Subsequently, other centers applied TORS for resection of early cancers in the hypopharynx.

Several centers subsequently showed that TORS resection of early stage cancer of the upper aerodigestive tract was technically feasible and TORS resection was able to obtain clear resection margins. The quoted advantage of TORS compared to other endoscopic resection methods like endoscopic laser surgery included better access to tumors. The angled endoscope and EndoWrist® allowed access to tumors outside the line of sight, which would not be accessible with traditional endoscopic instruments and CO₂ laser. After an initial learning phase, the operating time including robot setup time was comparable to traditional endoscopic surgery. The postoperative recovery, including time to return to oral diet and hospital stay, was also comparable. Figures 1–5 illustrate a typical case of robotic tonsillectomy for T1 cancer of the tonsil.

TORS and laser surgery are not mutually exclusive technologies. Several centers had adapted the use of fiber laser delivery with the da Vinci robot in resection of oropharyngeal, laryngeal, and hypopharyngeal lesions. The advantages of the laser included precise incision, minimal
adjacent tissue damage, and excellent tissue hemostasis.\textsuperscript{19–22} The EndoWrist\textsuperscript{®} and angled telescope of the da Vinci surgical robot allow delivery of laser to areas previously not able to be reached by traditional delivery methods like transoral laser microscopic surgery.

Short-term oncological results of TORS have been shown to be comparable to other treatment methods like radical resection or concurrent chemoradiotherapy in several centers. Most of the short-term oncological outcomes were reports on the results of treating oropharyngeal cancers.\textsuperscript{23–31} Unfortunately, a high proportion of the patients in the above cohorts received postoperative radiotherapy or chemoradiotherapy, usually due to advanced nodal diseases. This makes it difficult to analyze the additional oncological effect of TORS as a treatment.

In the West, oropharyngeal cancer became the dominant type of cancer in the upper aerodigestive tract from the year 2000.\textsuperscript{32} The majority of the oropharyngeal cancers harbor the human papilloma virus (HPV).\textsuperscript{33} Ang et al showed that HPV-related oropharyngeal cancer had a markedly improved survival after definitive treatment with chemoradiotherapy, and HPV was shown to be a strong and independent prognostic factor in oropharyngeal cancer.\textsuperscript{34} The 3-year overall survival of the HPV-positive oropharyngeal cancer patients in Ang’s cohort was 82.4%, compared to 57.1% in the HPV-negative patients. Primary chemoradiotherapy was shown to affect the swallowing function of the patients to an extent that the patient could become feeding-tube dependent.\textsuperscript{33,35,36} Higher dose of
radiotherapy and the addition of chemotherapy were shown to be a predictor of poor swallowing outcome.\textsuperscript{34,36,37} As the survival of HPV-related oropharyngeal cancer is excellent, minimizing the long-term complications after treatment is necessary.

Advocates of TORS and primary surgical treatment argued that with primary surgery (TORS or other methods) to resect the local disease, and conservative neck dissection to control nodal disease, a significant portion of the patients can avoid high-dose radiotherapy or the addition of chemotherapy. This would in turn lead to a better long-term swallowing outcome. This is the advantage of incorporating TORS in the overall management of HPV-related oropharyngeal cancer, which is otherwise managed equally well with chemoradiotherapy in terms of survival outcome. Phase II randomized clinical trials are now ongoing or under planning to define the role of TORS in HPV-related and HPV-unrelated cancer of the oropharynx.\textsuperscript{38}

There are fewer reports on the oncological efficacy of TORS in management of laryngeal cancer.\textsuperscript{14,39–42} The reported cohorts were of smaller size with a median of nine patients (range three to 18). All resections in the five cohorts achieved negative surgical margins. The initial outcomes were comparable to other modalities of treatment but there were no obvious advantages compared with other modalities of treatment like transoral laser microsurgery. A large multicenter report on the experience of TORS on 82 laryngeal cancers commented that only a small portion of patients would not be able to receive transoral laser microsurgery.\textsuperscript{17}

To date, there are two reports on performing total laryngectomy with the da Vinci surgical robot, but both are small case series with no oncological outcome measurement.\textsuperscript{43,44} The advantage of robotic total laryngectomy is unknown at present.

Oncological results for TORS resection of hypopharyngeal cancers are also lacking. The largest series consisted of 23 patients with 16 T1–T2 tumors.\textsuperscript{45} Sixty-nine percent received adjuvant radiotherapy or chemoradiotherapy. The 3-year overall survival was 89%. Lörincz et al reported their experience in five patients using TORS to resect early (T1–T2) cancer of the pyriform fossa.\textsuperscript{46} They were able to achieve en bloc resection with at least 4 mm microscopic clear margins.

For TORS to be a successful minimally invasive surgery, the functional outcome should be as important as the oncological outcome. The majority of the functional outcome studies concentrated on swallowing function, as dysphagia is the main long-term morbidity of the alternative organ preservation treatments. The majority of the functional outcome reports are from TORS resection of oropharyngeal cancer. Hutchison et al published a systematic review of the functional outcome after TORS for oropharyngeal cancer in 2014.\textsuperscript{47} The review included 12 trials with 441 patients. The conclusion was that patients who underwent TORS for oropharyngeal cancer had a lower gastrostomy utilization rate when compared to published benchmarks of radiotherapy or chemoradiotherapy cohorts. The subjective swallowing symptom scores for TORS patients were comparable to radiotherapy cohorts.

Richmon et al reported an analysis of 9,601 patients treated for oropharyngeal cancer with ablative surgery from 2008–2009 in the USA from the discharge data of the Nationwide Inpatient Sample.\textsuperscript{48} TORS was associated with shorter hospital stay (mean –1.5 days) and lower hospital related costs (mean –US$4,285) after controlling for comorbidities, extent of surgery, and type of hospital. The study did not factor in the capital cost of the da Vinci surgical robot so it was difficult to extrapolate the real cost saving. The study also showed that patients who received TORS had a lower rate of gastrostomy and tracheostomy when compared with other surgical ablative procedures. Chung et al reported a nationwide analysis of clinical and cost outcome of TORS for oropharyngeal and oral tongue cases from 2008–2011 in the United States, and showed that TORS lateral oropharyngectomy and tongue base resection had clinical and cost benefits. There was no benefit with using the robot for oral tongue cancer.\textsuperscript{49}

An emerging unique application of TORS in the management of head and neck malignancies is in the workup of the metastatic neck lymph node of unknown primary. Mehta
et al first reported a case series of ten patients with metastatic neck lymph node of unknown primary who underwent TORS resection of base of tongue, and the primary cancer was identified in nine out of ten cases. Abuzeid et al reported a case of identifying the primary cancer in the base of tongue after TORS resection of base of tongue, and argued that the ability of TORS to identify the primary would spare patients from wide-field irradiation if the primary was unable to be identified. Durmus et al showed in their cohort of 22 patients that the use of TORS tonsillectomy and base of tongue resection as part of the diagnostic and therapeutic procedure for unknown primary had excellent short-term quality of life outcome. Literature is still lacking in comparison of the incorporation of TORS versus standard workup of endoscopy and imaging in the workup of metastatic neck lymph node of unknown primary.

Apart from ablative surgery, the da Vinci surgical robot has also been employed in reconstruction of defects in the upper aerodigestive tract after resection of the primary tumor. Selber et al demonstrated in the dissection laboratory the feasibility of inserting a microvascular free flap in the oropharynx and microvascular anastomosis of the free flap in a cadaver. The advantage of the da Vinci surgical robot in flap inset was the ability to visualize and suture in the confined space of the base of tongue and oropharyngeal wall, while the disadvantage was the lack of tactile sensation in tying knots, requiring the surgeon to use vision to inspect the tightness of the knots. Since then, Selber et al and other groups have published their case series on robotic inset of free flaps.

Despite the widespread use of TORS, robotic-assisted reconstructions of head and neck defects have not gained popularity. Apart from the additional cost incurred with using the robot, there are several reasons for the lack of popularity of robotic-assisted reconstructions in the head and neck region. Firstly, lesions resected with TORS are usually small and healing by primary closure, or local rotational mucosal flap would be adequate. Larger tumors are usually contraindicated for the TORS approach and are usually resected with traditional transcervical approaches with or without mandibulotomy. These defects would then be reconstructed in a traditional way. Secondly, the loss of tactile sensation may not be compensated by the superior visualization offered by the robot. Thirdly, the da Vinci surgical robot is still bulky and takes time to set up in preparation for use in flap insetting and microvascular anastomosis. Surgeons may not be willing to add this extra setup time in these already long operations, though Katz et al argued that the setup time for the robot is similar to the setup time of the microscope. Lastly, tremor of the surgeon during microvascular anastomosis is not an insurmountable obstacle and, with practice, most microvascular surgeons would be able to overcome hand tremor and perform microvascular surgery well. The benefit of tremor filtration offered by the da Vinci surgical robot may be marginal.

Apart from application in head and neck oncology, the da Vinci surgical robot has also been used for benign conditions of the head and neck region, most commonly for the resection of hypertrophic tongue base tissue in obstructive sleep apnea syndrome (OSAS). Principles and setup for TORS resection of base of tongue can be easily adapted to resect hypertrophied lingual tonsils in patients with OSAS. Several reports have been published in the literature on the use of the da Vinci surgical robot for resection of base of tongue and other redundant oropharyngeal soft tissue in OSAS. Further research is required to compare the efficacy and cost–benefit ratio in using the robot in comparison to other modalities like radiofrequency ablation and coblation lingual tonsillectomy. The risks associated with TORS procedures in OSAS are similar to other procedures in sleep apnea surgery, and special monitoring and nursing care need to be offered in the postoperative period to maximize patient safety.

**Application of the da Vinci surgical robot in the nasopharynx and skull base**

Endoscopic endonasal surgery has gained significant advancements in the past 2 decades due to the improvement in surgical instruments and increased understanding of the endoscopic anatomy of the nasal cavities, paranasal sinuses, anterior skull base, and central skull base. Currently, a two surgeon four hands technique is a standard approach for endoscopic endonasal resection of skull base lesions. The next logical step in endoscopic endonasal surgery is the application of robotic surgery.

The first preclinical trial on the use of the da Vinci surgical robot in the skull base was started in 2005 by the University of Pennsylvania group. They performed cadaveric dissections and showed the feasibility of using the robot to dissect in the parapharyngeal space and infratemporal fossa. The access to the parapharyngeal space and infratemporal fossa was through a transoral route with incision of the ipsilateral tonsillar pillar. They also noted that the absence of bone instruments would hamper resection of lesions involving the bony skull base. The group later described their case series of resecting benign tumors in the parapharyngeal space with the robot.
Hanna et al described their approach to the anterior and central skull base using the da Vinci surgical robot on cadaveric dissection. Instead of employing a pure transoral approach, they created two “ports” on the anterior maxillary wall by two sublabial incisions and bilateral maxillary antrostomies (Caldwell-Luc approach). The middle meatal antrostomies of the maxillary sinuses were enlarged and the robotic arm could be advanced into the nasal cavity to reach the skull base. The endoscope was inserted into the nasal cavity through one of the nostrils. They demonstrated resection of lesions in the pituitary fossa, planum sphenoidale, nasopharynx, pterygopalatine fossa, and cribriform plate with the robotic arms. More importantly, they demonstrated the ability to perform watertight suturing of the anterior cranial fossa dura with the surgical robot. Some of the dissection was performed with prototype instruments that can remove bone in the skull base (E Hanna, personal communication, December 2013). These prototype instruments, unfortunately, have not been marketed and are not available for clinical use.

In 2010, Lee et al reported their investigation of various approaches to the skull base with the da Vinci surgical robot on cadaveric dissection. They commented that with transoral route and elevation of the soft palate, a 0-degree lens would be adequate for visualization of lesions in the foramen magnum level. For lower and middle clivus, a 30-degree upward-looking telescope setup would be required. Using a small 8.5 mm 30-degree telescope, they could visualize the sella after removing the anterior sphenoid wall and sphenoid floor with conventional endoscopic drills. Unfortunately, clutter of robotic arms limited the range of movements of the robotic arms. In an effort to circumvent the clutter of robotic arms, the group had previously described placement of two ports through the submandibular soft tissue facing superiorly and allowed placing the two robotic arms outside the oral cavity angled superiorly. McCool et al also described a similar setup in which the third robotic arm was placed in the port inserted above the hyoid bone into the oropharynx.

Ozer and Waltonen described the first robotic nasopharyngectomy on a cadaver. To improve visualization of the nasopharynx, the soft palate was split in the midline and retracted laterally. They were able to resect the entire nasopharynx mucosa and both eustachian tube openings to expose the clivus and prevertebral fascia. The authors commented that the potential advantages of the robotic approach included no facial incisions and no osteotomies.

Dallan et al performed cadaveric dissection for robotic nasopharyngectomy using the submandibular ports and 0-degree endoscope introduced through one nostril. They commented that this approach offered a better visualization of the roof of the nasopharynx and reduced conflicts of the robotic instruments and endoscope during the dissection.

Wei and Ho described the first clinical case of robotic nasopharyngectomy for recurrent nasopharyngeal carcinoma through a transoral approach. The approach was similar to the approach described by Ozer and Waltonen in their cadaveric dissection experiments. Since then, there have been further reports on the development of robotic nasopharyngectomy, including combined approach with endoscopic endonasal approach. Tsang et al reported the first clinical case series of 12 patients who underwent robotic nasopharyngectomy for small recurrent cancer. The early results were comparable with open surgery with less morbidity.

O’Malley et al first described the use of TORS to resect parapharyngeal space tumors. Since then, there have been several large case series reporting the use of TORS for parapharyngeal tumors. Chan et al performed a systematic review of the use of TORS in resection of parapharyngeal tumors. They concluded that the advantages of using TORS compared to transcervical approach included the absence of a neck scar and absence of first bite syndrome after operation. Unfortunately, TORS approach needs an incision through the oropharyngeal mucosa and superior constrictor muscles and higher rate of capsule rupture during dissection. TORS for resection of parapharyngeal tumors may be advantageous in lesions situated medial to the carotid vessels. An external approach will require retraction of the carotid vessels for exposure and resection of the lesion, which has its associated risks. Vidhyadharan et al reported the use of TORS for resection of a second branchial arch cyst medial to the carotid vessels, and Ansarin et al reported a series of parapharyngeal space tumors in the post-styloid compartment resected with TORS approach.

**Challenges and future developments**

The da Vinci surgical robot was not primarily designed to be deployed in the head and neck region. It is still too bulky to use in places like the anterior skull base. A new surgical robot (model: da Vinci Xi) with a smaller footprint and less chance of arms collision has already been launched in the market, but unfortunately has not been designed for transoral use and FDA approval for TORS has not been sought. Smaller robotic instruments with flexible or semiflexible arms are being designed. Flexible robots could be introduced through the oral cavity and turn upwards to operate in the nasopharynx, negating the requirement for a straight-line access for the current rigid robotic instruments. Richmon presented his
Robotic Surgery: Research and Reviews 2015:2

Table 1 List of transoral robotic procedures mentioned in the review, excluding cadaveric experiments

<table>
<thead>
<tr>
<th>Procedure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Robotic radical tonsillectomy</td>
</tr>
<tr>
<td>Robotic tongue base resection</td>
</tr>
<tr>
<td>Robotic supraglottic laryngectomy</td>
</tr>
<tr>
<td>Robotic partial laryngectomy</td>
</tr>
<tr>
<td>Robotic hypopharyngectomy</td>
</tr>
<tr>
<td>Robotic total laryngectomy</td>
</tr>
<tr>
<td>Robotic-assisted transoral laser excision (oropharynx, larynx, and hypopharynx)</td>
</tr>
<tr>
<td>Robotic-assisted insetting of flaps</td>
</tr>
<tr>
<td>Robotic microvascular anastomosis for free flaps</td>
</tr>
<tr>
<td>Robotic lingual tonsillectomy for sleep apnea</td>
</tr>
<tr>
<td>Robotic resection of parapharyngeal tumors</td>
</tr>
<tr>
<td>Robotic nasopharyngectomy</td>
</tr>
</tbody>
</table>

work on using the Flex® System robot to perform resection of the nasopharynx without transgressing the palate in a cadaver.84

Lack of tactile feedback is a major criticism of robotic surgery and this is also true for TORS. Robotic surgeons currently substitute the tactile sensation mainly with visual cues to a certain extent, but visual cues could not entirely replace tactile sensation. VerroTouch is an early attempt to produce an external add-on to the da Vinci surgical robot to provide haptic feedback to the operating surgeon.75,85 The system is not required to be built into the current da Vinci robot, but instead is an after-market add-on. The sensors are placed on the wands of the robotic instruments just distal to the mounting points of the robotic arms. The vibration actuators are placed on the control handles of the console. As the robotic instruments slip or hit tissue, the sensor will sense the acceleration/deceleration. The electrical signals from the sensors will be filtered, amplified, and converted to vibrations in the finger-tips. A small-scale survey of the advantage of the VerroTouch system has been completed by eleven robotic surgeons and the majority welcomed the addition of the haptic feedback, but none found it essential.

Development of robotic instruments for bone removal will definitely improve the application of the surgical robot in fields like spine surgery and anterior skull base surgery, where bone removal constitutes a significant proportion of the operation. Currently, traditional endoscopic drills and burs are used if bone removal is required during TORS for the skull base. Developing small-diameter articulated robotic drills and burs suitable for TORS is an engineering challenge. Alternatively, other approaches for bone removal may be more suitable for development into robotic instruments. Ultrasonic aspirators like Sonopet (Stryker, Kalamazoo, MI, USA) can precisely remove bone and have been used in endoscopic endonasal skull base surgery.86 Currently, it is the small commercial demand that limits the development of robotic versions of these instruments.

The development of alternative energy-source instruments for hemostasis and their integration with robotic instruments will be a welcomed invention. Currently, TORS that use only monopolar and bipolar cautery are mostly being used for hemostasis. The current robotic ultrasonic dissector is too bulky and lacks articulation. An ultrasonic dissector would be a better instrument for dissection around areas prone to bleeding like venous plexus in the pterygoid plexus and parapharyngeal space.

The surgical navigation system can overcome the difficulty of identifying and avoiding injury of vital structures, especially the internal carotid artery in robotic nasopharyngectomy. The currently available optic or electromagnetic types of navigation systems in the market have difficulty in working with the surgical robot. A surgical robot with integrated navigation system is under active development and we should see clinical application in the near future.87

With the development of computer and imaging technology, augmented reality in surgical imaging is now available for clinical use. Augmented reality allows for the images of radiology scans to be overlaid on the endoscopic view during operation. This will allow better identification of pathologies and critical neurovascular structures buried deep underneath normal tissues. Integration of augmented reality with surgical robots has been under research for some time and clinical products should be available soon.88

Conclusion

In nearly a decade of development, TORS has emerged from a niche experimental surgery to mainstream management of early cancers in the oropharynx. It also has limited use in resecting cancers in the larynx and hypopharynx, and tumors in the skull base. TORS for benign conditions, especially tongue base resection for obstructive sleep apnea, has rapidly been adopted. TORS can be considered as the continuation of the paradigm shift first initiated by endoscopic surgery. With the advancement of technology, newer surgical robots, especially ones designed for application in TORS, will emerge soon. With the advent of these new technologies, surgeons must be prepared for another paradigm shift.

Disclosure

The author received a clinical research grant from Intuitive Surgical Inc. in 2012 for clinical research on robotic
assisted nasopharyngectomy. The author reports no other conflicts of interest in this work.

References


